Basilea gibt Abschluss der Patientenrekrutierung für Phase-1-Studie mit oralem BAL101553 bei Hirntumoren bekannt

NEXT STORY
New Data From Aslan’s Study of Varlitinib in China Accepted as Late-Breaking Oral Presentation at 2019 CSCO Annual Meeting
PREV STORY
Press release Biocartis NV: Invitation to the Special Shareholders’ Meeting
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Orion Group Financial Statement documents 2020, Corporate Governance Statement and Remuneration Report published

author_avatar
NASDAQ Market News

Pfizer and BioNTech Celebrate Historic First Authorization in the U.S. of Vaccine to Prevent COVID-19

author_avatar
NASDAQ Market News

Astellas Receives Positive CHMP Opinion for EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease

author_avatar
NASDAQ Market News